For this reason, the dual binding inhibitors, which target both PAS and CAS, have become more promising in AD treatment : since they wil not only alleviate the cognitive deficit of AD patients by elevating ACh levels but also act as disease-modifying agents delaying amy-loid plaque formation.
In normal brain,AChE is more active than BuChE and hydrolyzes about 80 % of ACh.
However,as AD progresses, the activity of AChE decreases, while that of BuChE significantly rises becoming a modulator to regulate ACh levels in cholinergic neurons.